Who is sponsoring NCT00441415?

NCT00441415 is sponsored by Galderma R&D.

What condition does NCT00441415 study?

NCT00441415 studies Acne Vulgaris.

What is the status of NCT00441415?

NCT00441415 is currently COMPLETED.

Last reviewed 2021-02-16 · How we verify

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 0.1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris

NCT00441415 Phase 3 COMPLETED

The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in Subjects with acne vulgaris after a 12-week treatment period.

Details

Lead sponsor	Galderma R&D
Phase	Phase 3
Status	COMPLETED
Enrolment	272
Start date	2007-02
Completion	2007-10

Conditions

Acne Vulgaris

Interventions

Adapalene BPO

Primary outcomes

Percent change from Baseline in total lesion count (sum of non inflammatory and inflammatory lesions) at week 12.

Countries

United States